Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 13 Best Debt Free Dividend Stocks to Buy Now. Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) On December 12, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $768 from $767 and kept an Equal Weight rating. The firm expects many of the policy concerns that weighed on biopharma this year to fade in 2026. As those pressures ease, attention is likely to sh ...

March S&P 500 E-Mini futures (ESH26) are trending down -0.03% this morning as trading resumed after the Christmas holiday, with activity subdued and volumes expected to remain light ahead of a shortened New Year’s week. Higher bond yields today are weighing on S&P 500 futures. The 10-year T-note yield rose two basis points to 4.15%. More News from Barchart In Wednesday’s trading session, Wall Street’s three main equity benchmarks closed higher, with the S&P 500 posting a new record high. Nike (NKE) cl ...

Group 1 - Nvidia Corp. shares increased to $190.16 in overnight trading after announcing a non-exclusive licensing agreement with AI chip startup Groq, which covers its inference technology [1][1][1] - Dynavax Technologies Corp. shares surged 38.2% to close at $15.38 following Sanofi's announcement to acquire the vaccines company [1][1][1] - Sobr Safe Inc. shares jumped 82.3% to close at $2.37 after announcing definitive agreements to issue 1.29 million shares of common stock at $1.55 per share in a private placement [1][1][1] Group 2 - Davis Commodities Ltd. reported revenue of $95 million for the six months ending June 30, a 42.1% increase from $66.9 million a year earlier, but shares fell 8.9% to close at $0.24 [1][1][1] - Biohaven Ltd. disclosed that its Phase 2 proof-of-concept study of BHV-7000 in major depressive disorder did not meet its primary endpoint, with shares gaining 3% to close at $10.81 [1][1][1]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Core Viewpoint - Dynavax Technologies Corp. is set to be acquired by Sanofi for $2.2 billion, leading to a significant increase in its stock price by 38.19% to $15.38 on the announcement day [1][5]. Group 1: Acquisition Details - Dynavax has officially entered into an agreement with Sanofi to acquire all outstanding shares at a price of $15.50 each, representing a premium of approximately 39% over its closing price on December 23 [2]. - The acquisition will enhance Sanofi's presence in adult immunization, particularly through Dynavax's adult hepatitis B vaccine, Heplisav-B, which offers a two-dose regimen that provides faster seroprotection compared to traditional three-dose vaccines [3]. Group 2: Vaccine Portfolio and Development - The acquisition includes Dynavax's shingles vaccine candidate (Z-1018), currently in phase 1/2 clinical development, along with other vaccine pipeline projects [4]. - Dynavax's CEO emphasized that joining Sanofi will leverage global scale and expertise to maximize the impact of their vaccine portfolio, addressing significant public health needs [5].

U.S. financial markets are observing a full closure today, Thursday, December 25, 2025, in celebration of the Christmas holiday. Trading on both the New York Stock Exchange (NYSE) and Nasdaq is suspended for the entire day, with normal operations set to resume on Friday, December 26, 2025. This pause follows a shortened, yet record-setting, trading session on Christmas Eve, Wednesday, December 24, where major indexes continued their upward trajectory, fueling hopes of a "Santa Claus rally" to close out the ...

Group 1: Acquisition Details - Sanofi will commence a cash tender offer to acquire all outstanding shares of Dynavax Technologies at $15.50 per share, representing approximately $2.2 billion in total equity value [2] - The offer price reflects a 39% premium over Dynavax's closing price on December 23 and a 46% premium over its three-month volume-weighted average price as of December 23 [2] - The Dynavax board has unanimously approved the transaction [4] Group 2: Product and Pipeline - The acquisition includes HEPLISAV-B, an adult hepatitis B vaccine available in the U.S., which is administered in two doses over one month, unlike the traditional three-dose schedule [3] - Sanofi's Executive Vice President of vaccines stated that Dynavax enhances Sanofi's adult immunization presence by adding differentiated vaccines [3] Group 3: Regulatory and Financial Aspects - The acquisition is subject to regulatory approvals, including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions [5] - Sanofi intends to fund the acquisition with available cash [6] - Dynavax was advised by Centerview Partners LLC and Goldman Sachs & Co. LLC during the transaction [6] Group 4: Stock Performance - Shares of Dynavax surged 38.19% in regular trading on Wednesday, closing at $15.38, before slightly tapering to $15.37 in after-hours trading [1] - The stock has a market capitalization of $1.81 billion and has gained 18.04% over the past 12 months and 55.98% over the last six months [7] - Currently, the stock is trading at 98.3% of its 52-week range, indicating it is near its highs, which reinforces bullish sentiment [8]

12月25日，刘波副司长会见赛诺菲中国区副总裁朱海鸾，就企业对华合作情况进行交流。 ...

法国制药巨头赛诺菲于当地时间12月24日宣布，已与美国疫苗公司德纳维制药（Dynavax Technologies）达成协议，将以约22亿美元（约合19亿欧元）的现金收购后者全部股份。该交易已获德 纳维制药董事会批准。 根据赛诺菲发布的声明，此次收购报价为每股15.50美元。这一价格较德纳维制药在12月23日（周二） 11.13美元的收盘价溢价39%。交易预计将于2026年第一季度完成。赛诺菲方面表示，此次收购将使用 公司现有现金储备支付，且不会对其2025年的财务业绩预期产生影响。 此次收购的背景，正值美国疫苗政策经历重大调整。美国卫生部长小罗伯特·肯尼迪对疫苗领域持批评 立场，已削减疫苗研究经费并撤换了美国疾病控制与预防中心负责人。近期，该机构的顾问委员会取消 了一项长期建议，不再建议所有美国新生儿接种乙肝疫苗。赛诺菲此前曾表示，疫苗接种率下降部分源 于围绕疫苗的"负面舆论氛围"。其竞争对手葛兰素史克也曾警告美国疫苗销售面临压力。 值得注意的是，赛诺菲在宣布此次收购的数分钟前，刚刚披露其用于治疗多发性硬化症的在研药物托布 替尼（Tolebrutinib）未能获得美国食品药品监督管理局的批准。赛诺菲研发负责 ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Sanofi ( SNY ) announced the acquisition of Dynavax ( DVAX ) for $15.50 per share, or $2. ...